Unlocking the Therapeutic Potential of Neuroplastogens
Neuroplastogens are the Next Big Therapeutic Opportunity
Negev Labs Drives Value Creation
A Disciplined and Efficient Approach to Company Building
01
Source, validate and secure valuable IP
02
Build disease-focused biopharma companies
03
Rapidly advance to human proof-of-concept trial
04
Maximize returns via strategic exits
Negev Labs' distinctive value proposition lies in its proactive and efficient approach to company building. We transcend the limitations of traditional incubators and accelerators by directly acquiring or licensing promising intellectual property (IP) and building laser-focused, capital-efficient proto-companies. These proto-companies are strategically designed to rapidly de-risk assets and achieve significant value inflection points.
Management Team
Ken Belotsky
Managing Partner
Partner at Negev Capital since 2021.
15 years managing startups. Co-founder of Bright Box acquired by Zurich Insurance in 2018. Co-founder of BrightConsult acquired by Incadea in 2011.
Kostia Adamsky
Partner, Chief Operating Officer
Principal at Negev Capital . VP Ops at Levco Pharmaceuticals Ltd, CEO & VP Ops at Regenera Pharma LTD., Director and co-CEO at Targia Pharmaceuticals. PhD in cell biology from Weizmann Institute.
Heresh Rezavandi
Partner, Strategy & Pharma Partnering
14+ years' experience in life science R&D, portfolio, search and evaluation, BD&L, marketing, strategy in global roles at UCB, Bayer, Roche and Angelini. PhD in Biochemistry.
Shlomi Raz
Partner
President & CBO of Beckley Psytech and Founder & CEO of Eleusis Therapeutics. Managing Director at Goldman Sachs. MA from NYU and BS from Georgetown University.
Contact us
Thank you for getting in touch!
We appreciate you contacting us. One of our colleagues will get back in touch with you soon!
Have a great day!